Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
Okay, this is an incredibly challenging situation with immense pressure from multiple fronts. My priority is unwavering: patient safety comes first, followed by mitigating harm and navigating the crisis with integrity. Delay is not an option when patient safety is potentially compromised.Read the full answer
As CEO, my primary fiduciary and ethical duty is to patients, regulators, and long-term shareholder value. The "6-month reporting timeline" cited by legal is almost certainly a misunderstanding of regulatory processes (likely conflating initial adverse event reporting with full label amendment review).Read the full answer